n-(4-aminophenethyl)spiroperidol has been researched along with vasoactive intestinal peptide in 1 studies
| Studies (n-(4-aminophenethyl)spiroperidol) | Trials (n-(4-aminophenethyl)spiroperidol) | Recent Studies (post-2010) (n-(4-aminophenethyl)spiroperidol) | Studies (vasoactive intestinal peptide) | Trials (vasoactive intestinal peptide) | Recent Studies (post-2010) (vasoactive intestinal peptide) |
|---|---|---|---|---|---|
| 12 | 0 | 3 | 10,873 | 123 | 1,221 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agui, T; Munemura, M; Sibley, DR | 1 |
1 other study(ies) available for n-(4-aminophenethyl)spiroperidol and vasoactive intestinal peptide
| Article | Year |
|---|---|
Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Binding, Competitive; Cell Membrane; Diethylstilbestrol; GTP-Binding Proteins; Guanine Nucleotides; Guanylyl Imidodiphosphate; Male; Organ Size; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Inbred F344; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone; Vasoactive Intestinal Peptide | 1989 |